STAT3 and lung carcinoma: Li et al. reported that inhibition of EGFR by erlotinib induced STAT3 phosphorylation on Tyr705 together with increased Bcl2/Bcl-XL at both the mRNA and protein levels in human lung cancer cell lines [83].